Sterling Biotech Limited announced audited standalone earnings results for the quarter and fifteen months ended March 31, 2016. For the quarter, the company reported net sales/income from operations of INR 1,131.208 million against INR 1,006.299 million a year ago. Loss from operations before other income and finance costs was INR 530.582 million against INR 573.420 million a year ago. Loss from ordinary activities after finance costs but before tax was INR 1,359.564 million against INR 1,337.356 million a year ago. Net loss for the period was INR 918.464 million against INR 903.456 million a year ago. Diluted loss per share before and after extraordinary items was INR 2.12 against INR 2.09 a year ago. For the fifteen months, the company reported net sales/income from operations of INR 5,239.902 million, loss from operations before other income and finance costs of INR 2,790.227 million, loss from ordinary activities after finance costs but before tax of INR 6,938.046 million, net loss for the period was INR 4,686.946 million and diluted loss per share before and after extraordinary items of INR 10.82.